NCT04624672 (NOVO-GLP1) is a Phase 4 clinical trial of Semaglutide (1 Mg Dose) in Diabetes Mellitus, Type 2, sponsored by Geisinger Clinic.

Who is sponsoring NCT04624672?

NCT04624672 is sponsored by Geisinger Clinic.

What drugs are being tested in NCT04624672?

Interventions in NCT04624672: Semaglutide (1 Mg Dose), Placebo.

What condition does NCT04624672 study?

NCT04624672 studies Diabetes Mellitus, Type 2.

Is NCT04624672 still recruiting?

NCT04624672 is currently terminated. Last updated 14 November 2023.

Are results published for NCT04624672?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-11-14 · How we verify

NCT04624672: NOVO-GLP1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of GLP-1 for Diabetic Bariatric Patients

Terminated Phase 4 Results posted Last updated 14 November 2023

What this trial tests

Phase 4 trial testing Semaglutide (1 Mg Dose) in Diabetes Mellitus, Type 2 in 3 participants. Terminated before completion.

Timeline

25 August 2021

Primary endpoint
18 July 2022

17 August 2022

Quick facts

Lead sponsor	Geisinger Clinic
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	3
Start date	25 August 2021
Primary completion	18 July 2022
Estimated completion	17 August 2022
Sites	1 location across United States

Drugs / interventions tested

Semaglutide (1 Mg Dose) — full drug profile →
Placebo

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Geisinger Clinic

Who can join

Adults 18 to 75, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Semaglutide (1 Mg Dose)

Trials testing the same drug.

NCT07374328 — Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus · Phase 1, PHASE2 · recruiting

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Geisinger Clinic trials

Trials by the same sponsor.

NCT07197801 — Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Diso · NA · recruiting
NCT06936709 — Perioperative Colchicine for TKA · Phase 4 · not yet recruiting
NCT07042477 — Integrated Telemedicine Program Evaluation · NA · recruiting
NCT07028398 — CMSL Ambulatory Sensitive Condition Nudge Study 2 · NA · recruiting
NCT06696066 — PEERS Pilot: Peer Recovery Support Program to Support Engagement in Medication for Opioid Use Disorder · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04624672 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Geisinger Clinic
Last refreshed: 14 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04624672.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing